For scientists to improve cancer treatments with targeted therapeutic drugs, they need to be able to see proteins prevalent in the cancer cells. This has been impossible, until now. Thanks to a new microscopy technique, University of Akron researcher Dr. Adam Smith, assistant professor of chemistry, has observed how clusters of epidermal growth factor receptor (EGFR) – a protein abundant in lung and colon cancers, glioblastoma and others – malfunctions in cancer cells.
“We can directly observe protein clusters, in a living cell membrane, that are invisible to traditional methods. This opens up the possibility to directly measure the effect of drugs on the target proteins,” Smith says.
Smith’s work lies at the heart of current-day cancer research, which focuses on developing targeted drugs that kill cancer cells without the collateral damage associated with traditional treatments like chemotherapy.
Specifically, Smith used a cutting-edge photon-counting technique, which enables scientists to measure the cluster size of EGFR proteins. The technique represents a significant advancement from studying the cultures with a traditional microscope, which cannot visually capture objects as small as the EGFR clusters, according to Smith, a lead author of “Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor,” * published in the journal Cell, which highlights the technique.
“Another difficulty with studying EGFR is that it’s located in the cell membrane, which can be thought of as a fence line that defines the cell boundary, but in reality it is more like an untamed hedge row,” says Smith, explaining how the new laser-based microscope technique overcomes that obstacle and allows scientists to study, in real time, how EGFR works in healthy cells and also how it malfunctions in cancer cells.
Smith’s subsequent work studying the interaction of drugs with the targeted EGFR “will significantly improve drug discovery, which too often relies on indirect measure of efficacy,” he says.
Article adapted by Medical News Today from original press release. Click ‘references’ tab above for source.
Visit our lung cancer section for the latest news on this subject.
Partners in Smith’s research include scientists from the University of California, Berkeley, and Columbia University. The National Cancer Institute, Howard Hughes Medical Institute and the U.S. Department of Energy provided funding for this research.
University of Akron
Please use one of the following formats to cite this article in your essay, paper or report:MLA
University of Akron. “Targeting Lung And Colon Cancers And Glioblastoma Using New Photon-Counting Technique.” Medical News Today. MediLexicon, Intl., 28 Feb. 2013. Web.3 Mar. 2013. <http://www.medicalnewstoday.com/releases/256935.php>
University of Akron. (2013, February 28). “Targeting Lung And Colon Cancers And Glioblastoma Using New Photon-Counting Technique.” Medical News Today. Retrieved fromhttp://www.medicalnewstoday.com/releases/256935.php.
Please note: If no author information is provided, the source is cited instead.
(Hover over the stars then click to rate)
Patient / Public:or
Add Your Opinion On This Article‘Targeting Lung And Colon Cancers And Glioblastoma Using New Photon-Counting Technique’Please note that we publish your name, but we do not publish your email address. It is only used to let
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.